



Non-invasive test for the detection of any harmful phase of MASLD

General Information

Description

OWLiver® is a blood test carried out under fasting conditions, which measures a panel of biomarkers all of them lipids. Such biomarkers are a reflection of the amount of fat and inflammation in the liver and, hence, allow to determine the degree of severity of metabolic dysfunction-associated steatotic liver disease (MASLD). All lipids are measured using ultra-high-performance liquid chromatography and mass spectrometry (UHPLC-MS). The relative concentrations of these biomarkers are analyzed in an algorithm that generates the OWLiver® final score, which is the probability of the patient's liver state approximating to either MASLD or MASH.

Clinical practice

MASLD Screening - To identify patients with MASLD at any stage of the disease for personalized management.

Avoid biopsy - Precise characterization of the disease avoiding biopsy.

Alteration origin - To discern if the alteration of the hepatic profile responds to the metabolic pathology or to another origin.

Clinical trials - To identify patients who are candidates for clinical trials.

Monitoring - To monitor the disease in patients who are candidates for pharmacotherapy.

Complete Diagnosis - To avoid the combination of non-diagnostic techniques that present heterogeneity and subjectivity of interpretation.

Registration and Marketing Authorization

- The OWLiver® Test is an IN VITRO DIAGNOSTIC medical device that has been developed and patented complying with directive 98/79/CE (CE MARKING).
- CPT / PLA Code 0344U (USA).

Deal Design

- We are looking for a Distributor and/or Licensing Partner having a relevant sales structure in Hepatology to do a proper promotion of the OWLiver® Test.
- Deal design consisting of a Licensing Agreement to promote and market the OWLiver® Test, which serum samples will be processed in a local Central Lab with a UHPLC-MS homologated by Laboratorios Rubiό, S.A.
- We are searching for the best Partners to develop trustful, fruitful and long-term business partnership.



55
years

We are **pharmacypathfinders**

Founded

1968

Location

Castellbisbal, Barcelona, Spain

Main Focus

CNS, Nephrology/Urology, Cardiovascular, Gastroenterology, Rheumatology/Orthopedic, Oncology/Radiotherapy, Gynecology.

About Rubiό

For 55 years Laboratorios Rubiό, a family-owned company, has been recognized for the development, manufacture and marketing of medicines with high therapeutic value for specialists as well as of certain drugs for life-threatening diseases, with long expertise in niche markets.

Laboratorios Rubiό's determination to meet the health needs of every single patient has led the company to be distinguished as per being pioneer of products targeted to low incidence diseases which affect only a small number of patients and that require the development of specific pharmaceutical products to treat them.

International Alliances and Partnering Strategy

Laboratorios Rubiό has established a strong network of partnerships through in and out activities and commercial distribution agreements. Laboratorios Rubiό has been in the export business since 1982 and has alliances in over 60 countries. Laboratorios Rubiό is constantly exploring new territories and partnerships.

Contact details:

Laboratorios Rubiό, S.A.
Industria 29, P.I. Comte de Sert
08755 Castellbisbal, Barcelona, Spain
Tel.: +34 937 722 509
Fax: +34 937 721 602
www.laboratoriosrubio.com

Contact:

afelis@labrubio.com